Bug#149728: Monoclonal Antibody Therapy 2004
> Strategies for Monoclonal Antibody Therapy 2004
> Therapeutic applications, products in clinical trials and future outlook
> 1st & 2nd July, Hilton Kensington Hotel, London
>
>
> * Monoclonal antibody therapies are becoming an important weapon in the fight against cancer, autoimmune diseases, transplant rejection
> and many other diseases/conditions.
>
> Monoclonal Antibodies Sales are forecast to grow by over 400% by 2009.
>
> * This conference will address all of the relevant issues in this growing sector; including methods to lower production costs and realise greater
> profits.
>
> Themes will include:
> * Handling cost issues of MAb treatment
> * Overcoming problems of antibody production
> * The future of MAb> '> s: transgenic proteins
> * Case studies: analysis of major drugs in the market
> * Case studies: potential of products in clinical trials
> * Case studies: innovative delivery systems
>
> Industry Leading speakers confirmed at this event:
> * Dr. Andrea Feyereislova, Clinical Science Leader for Herceptin, Roche
> * Bob Ward, Senior Director, Commercial Development Biologics and Small Molecules, Schering-Plough
> * Rene Imwinkelreid, Head of Lonza Biologics, Lonza Biologics
> * Dr. Joachim Kalmus, Clinical Development Oncology, Schering
> * Ralph Minter, Senior Research Scientist, Cambridge Antibody Technology
> * Dr. David Humphreys, Celltech R&D, Celltech
> * Stephen Squinto, Executive VP and Head of Research, Alexion Pharmaceuticals
> * Dr. Zhenping Zhu, Assistant Vice President Head, Antibody Technology, ImClone Systems
> * Dr. Herren Wu, Senior Director, Antibody Discovery & Protein Engineering, MedImmune
> * Dr. Lorin Roskos, Senior Director, Pharmacokinetics and Toxicology, Abgenix
>
> Who Should Attend? (job titles)
> * Senior Director, Antibody Discovery
> * Senior Scientist, Protein Technology Biosciences
> * Director, Antibody Technologies / Engineering
> * Director, Protein Engineering & Structure
> * Senior Director, Immunology
> * Head, Expression and Cell Science
> * Biologics Manufacturing Development Manager
> * Chief Technical Officer
> * Director, Preclinical R&D
> * Director, Product Development
> * Vice President, Research and Development
> - plus all senior representatives involved in monoclonal antibody production/research.
>
> Places at this event are limited, please call or email me now to secure your place
>
> - PRICING -
> Attend the:
> ** Conf. + pre conf. workshop GBP 1600.00 Plus VAT
> ** Conference only Fee: GBP1299.00 Plus VAT
> ** Pre conference workshop only Fee: GBP 650.00 Plus VAT
>
> - BOOKINGS -
> Booking is easy, simply contact Lorraine Lescure on:
> Telephone: +44 (0)20 8767 6711
> Fax: +44 (0)20 8767 5001
> Email: mailto:lorraine.lescure@visiongain.com
> Terms and conditions apply - see below.
>
> I look forward to hearing from you soon.
>
> Regards,
> Lorraine Lescure
> Account Manager
> Visiongain b2b Conferences
> Tel: +44 (0) 20 8767 6711
> http://www.b2b-conferences.com
> mailto:lorraine.lescure@visiongain.com
>
>
>
>
> Sponsorship Opportunities
> This event will provide unrivalled opportunities to promote your brand to an audience of senior level delegates.
> Options include:
> * Full Conference Sponsorship
> * Exhibition Stand/Booth
> * Promotional Inserts
> * Delegate Bag Sponsor
> * Cocktail Reception Sponsor
> Whatever your budget, whatever your requirements we can find you a way to place your brand at Monoclonal Antibody Therapy 2004.- reply to lorraine.lescure@visiongain.com for more info.
>
>
>
> - Agenda -
>
> Pre-Conference Interactive Workshop
> Monoclonal Antibodies:
> Pointers for Pre-Clinical Studies
> Wednesday 30th June 2004
> Workshop Leader: Hanne Kristensen, Diatec
>
> 09:40 Coffee and Registration
>
> 10:00 Introduction from workshop leader
> *> Overview of different technologies used by Diatec for
> production
> *> Practical examples
> *> Purification and downstream processing>
> *> Quality control
> *> Benefits of using a small, ISO 9001 certified company for
> research
> *> speed of production
> *> flexibility
> *> process development knowledge
>
> About the company
> Diatec.com is a Norwegian biotechnology company producing and
> selling monoclonal antibodies for world-wide distribution.
>
> Strategies for Monoclonal Antibody Therapy 2004
> Day One Thursday 1st July 2004
>
> Conference Chairman
> Bob Ward, Senior Director ,Commercial Development, Biologics and
> Small Molecules, Schering-Plough
>
> 9:00 Registration and coffee
>
> 9:30 Opening remarks from the Chair
>
> INTRODUCTION
>
> 9:40 How to Overcome Obstacles for Successful MAb Treatment
> *> Selecting the best MAb for a given target: a rational approach to
> MAb design goals
> *> Justifying first-in-human studies: preclinical efficacy, safety, and
> pharmacokinetics
> *> Bad target or wrong dose? Selection of the optimum clinical dose
> *> Managing the risk of immunogenicity
> Dr. Lorin Roskos
> Senior Director, Pharmacokinetics and Toxicology
> Abgenix
>
> 10:20 Contract Manufacturers: A Strategic Asset for your Company
> *> Contract manufacturers: filling the needs of biotech companies
> *> How has this niche industry grown?
> *> Reasons for success- full process development and regulatory
> support
> *> Stages: vector construction, cell line development to full scale
> manufacture
> Rene Imwinkelreid
> Head of Lonza Biologics
> Lonza Biologics
>
> 11:00 Morning Coffee
>
> ANTIBODY PRODUCTION
>
> 11:20 Process Development Requirements for Antibody
> Therapeutics
> *> Approach for antibody therapeutic products
> *> Generic process applications- cycle time reduction?
> *> Overcoming problems posed by production capacity
> *> Improving purification steps in the production process
> *> Regulatory considerations
> Cristina Glad
> Executive Vice President
> BioInvent
>
> 12:00 Strategies to Overcoming Immune Reactivity
> *> Problems of immune response and impact on therapeutic
> antibodies
> *> Strategies for chimeric and humanised antibodies
> *> Molecular imprinted polymer (MIP) for engineering synthetic
> antibodies
> *> Antibody engineering with target-activated enzymes
> Dr. Dee Athwal
> Senior Principal Scientist
> Celltech
>
> 12:40 Lunch
>
> 14:00 CAT-354: An IL13 Neutralising Antibody Optimised by
> Ribosome Display
> *> Ribosome display - a versatile technology for protein engineering
> *> Optimisation strategies - the combination of targeted and
> evolutionary approaches
> *> The results of antibody engineering - production of antibody CAT-354
> *> The next stages of pre-clinical development for CAT-354
> Ralph Minter
> Senior Research Scientist
> Cambridge Antibody Technology
>
> 14:40 CASE STUDY: Simplifying the Purification of Periplasmic Fab',
> the Creation and use of New E. coli Strains
> *> What are the benefits of Fab' production in the E. coli periplasm?
> *> Study of host protein mutation and co-purification with Fab
> *> The creation and use of new E. coli strains: chromosomal gene
> replacement
> *> What are the benefits of simplified purification regimes?
> *> The future: supplying large market indications with high quality
> drug
> Dr. David Humphreys
> Celltech R&D
> Celltech
>
> 15:20 Afternoon Tea
>
> THERAPEUTIC APPLICATIONS
>
> Over two-thirds of monoclonal antibody products are for transplant rejection,
> cancer, autoimmune diseases and infectious diseases
>
> 15:40 CASE STUDY: The Success of Remicade in treating
> Inflammatory Conditions
> *> The role of inflammatory cytokines in patients with crohn's disease
> - the cytokine tumour necrosis factor-alpha (TNF-alpha)
> *> How does this chimeric human: mouse antibody neutralise TNF-alpha?
> *> Role of remicade as an anti-TNF-blocking therapy for rheumatoid
> arthritis
> *> Clinical efficacy of infliximab
> - short and long term benefits
> - treatment of refractory Behcet syndrome
> *> The success of remicade- marketing approvals and global sales>
> Bob Ward
> Senior Director ,Commercial Development
> Biologics and Small Molecules
> Schering-Plough
>
> 16:20 CASE STUDY: Zevalin, a Novel Treatment Regime
> Zevalin is the first product with a monoclonal antibody that is
> combined with a radioactive chemical for the treatment of non-Hodgkin
> lymphoma
> *> Two part administration of Zevalin: screening and treatment
> *> Results from safety and efficacy studies
> *> Toxicity of treatment- limiting use
> *> How effective is it in patients who are refractory to antibody
> treatment?
> Dr. Joachim Kalmus
> Clinical Development Oncology
> Schering
>
> 17:00 Questions and Discussion
>
> 17:10 Summation of day one from conference chair
>
> 17:20 Close of Day One
>
> Strategies for Monoclonal Antibody Therapy 2004
> Day Two Friday 2nd July 2004
>
> 9:00 Registration and Coffee
>
> 9:30 Opening remarks from the chair
>
> 9:40 A Potent New Generation Anti-Tumour MUC1 Antibody
> *> How the antibody recognises the novel tumour-specific epitope TA-MUC1
> *> Results after 3 days of injection in the tumour of skin xenografted
> nude mice
> *> Tumour efficacy studies in mice
> *> Advantages over Pemtumomab: higher affinity, higher tumour
> specificity, lower binding to serum MUC1, and lower binding to
> PBMC
> *> Primary indication: GI cancers; secondary indications: other
> carcinomas, e.g. breast, ovarian, kidney cancer
> Dr. Steffen Goletz
> Chief Scientific Office
> Leiter Forschung & Entwicklung
> NEMOD Biotherapeutics GmbH & Co.KG
>
> 10:20 CASE STUDY: Herceptin, First FDA Approved Treatment for
> Breast Cancer
> *> Anti-cancer benefits of Herceptin
> - binding to HER2 and blocking growth factors
> - killing of cancer cells by the stimulation of the immune system
> *> Phase III trials: Herceptin in women with HER2 positive early stage
> breast cancer as adjuvant therapy
> *> Results of safety and efficacy studies
> Dr. Andrea Feyereislova
> Clinical Science Leader for Herceptin
> Roche
>
> 11:00 Morning Coffee
>
> 11:20 CASE STUDY: Synagis, only Monoclonal Antibody Approved
> to prevent Respiratory Syncytial Virus (RSV)
> *> First MAb successfully developed to combat infectious disease:
> mode of action
> *> Safety and efficacy studies
> *> Advantages over previous treatments
> *> Development of Numax
> - second generation of Synagis
> Dr. Herren Wu
> Senior Director
> Antibody Discovery & Protein Engineering
> MedImmune
>
> R&D: PRODUCTS IN CLINICAL TRIALS
>
> 12:00 CASE STUDY: The Potential of Erbitux
> *> Target: epidermal growth factor receptor
> *> Results of clinical studies
> - biological activity in a number of tumours
> *> Results from monotherapy
> - patients with colorectal cancer
> - metastatic colorectal cancer
> *> Efficacy and safety of Erbitux
> - patients with advanced solid tumours
> Dr. Zhenping Zhu
> Assistant Vice President Head
> Antibody Technology
> ImClone Systems
>
> 12:40 Lunch
>
> 14:00 CASE STUDY: Eculizumab, Humanised MAb in a New Class of
> Drugs
> *> Complement-5 inhibitors: activation methods
> *> Phase I/II results for rheumatoid arthritis, nephritis, systemic lupus,
> psoriasis, dermatomyositis and pemphigoid
> *> Predicted worldwide sales for different indications
> *> Orphan Drug Status: treating paroxysmal nocturnal hemoglobinuria
> Stephen Squinto
> Executive VP and Head of Research
> Alexion Pharmaceuticals
>
> FUTURE OUTLOOK: TRANSGENIC PROTEINS
>
> 14:40 Transgenic Plants: A New Model to meet Production Needs
> *> Potential of this segment
> - is it really a viable alternative?
> *> Large scale genetically engineered proteins an option for less
> complex proteins?
> *> Overcoming technical issues
> *> Challenges
> Dominique Mison
> Bio-industrial Director
> Meristem Therapeutics
>
> 15:20 Afternoon Tea
>
> INNOVATIVE DELIVERY SYSTEMS
>
> 15:40 CASE STUDY: Crystalline MAb Formulations for
> Subcutaneous Delivery
> *> MAb's: limitations of current administration and use>
> *> Altus Crystalomics TM protein crystallisation technology for
> subcutaneous delivery
> *> Pharmacokinetic profile and pharmacodynamic efficacy in vivo
> *> Advantages of delivery method: higher concentrations, low dose
> volume, low viscosity, high stability
> *> New opportunities for biopharmaceutical applications
> Dr. Sujit Basu
> Group Leader
> Parenteral Formulation and Delivery
> Altus Biologics
>
> 16:20 Questions and Discussion
>
> 16:40 Chairman Summation
>
> 16:50 Close of Conference
>
>
>
>
> Visiongain/B2B Conferences produce a range of timely business information material, if you wish to receive information of new products, simply reply to this email with ' New Products info' in the subject box
>
>
>
>
>
>
>
>
>
>
> Terms & Conditions
> NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for an invoice to be raised will be treated as an official booking and will be subject to the cancellation policy as outlined below.
> Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes, which are available on the day, will be sent to you. Unfortunately we are not able to transfer places between conferences and executive briefings. However if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by e-mail, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries.
>
> Indemnity: visiongain Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of visiongain Ltd. If such a situation arises we will endeavour to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses.
> To unsubscribe please reply with unsubscribe in the subject line.
> Data protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1998. Information contained about you may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. If you wish your details to be amended, please send your request to the Database Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG. Alternatively please reply with unsubscribe in the subject line. Please allow approximately 7 days for your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes come into effect.
>
>
>
>
>
>
>
>
>
>
>
>
>
>
#####################################################################################
This email has been scanned by MailMarshal, an email content filter.
#####################################################################################
Reply to: